Covalent small molecule drug discovery platform
Avila developed a novel chemistry approach ‘Avilomics’ to discover oral small molecule covalent inhibitors of proteases and kinases. Avilomics allows the design of highly specific compounds that irreversibly bind to the protein target to improve therapeutic index and clinical efficacy.
Avila’s most advanced product candidate, AVL-292, a highly selective Btk inhibitor was in Phase I clinical development at the time of its acquisition by Celgene.
CEO Katrine Bosley